A detailed history of Black Rock Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, Black Rock Inc. holds 12,414,773 shares of CYTK stock, worth $602 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
12,414,773
Previous 16,102,070 22.9%
Holding current value
$602 Million
Previous $1.34 Billion 35.26%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$63.75 - $108.06 $235 Million - $398 Million
-3,687,297 Reduced 22.9%
12,414,773 $870 Million
Q4 2023

Feb 13, 2024

BUY
$26.88 - $83.49 $12.6 Million - $39 Million
467,330 Added 2.99%
16,102,070 $1.34 Billion
Q3 2023

Nov 13, 2023

BUY
$29.46 - $36.61 $8.03 Million - $9.98 Million
272,567 Added 1.77%
15,634,740 $461 Million
Q2 2023

Aug 11, 2023

BUY
$32.62 - $40.75 $24 Million - $30 Million
736,791 Added 5.04%
15,362,173 $501 Million
Q1 2023

May 12, 2023

SELL
$33.36 - $45.71 $11.4 Million - $15.6 Million
-341,935 Reduced 2.28%
14,625,382 $515 Million
Q4 2022

Feb 13, 2023

BUY
$35.77 - $51.11 $14.2 Million - $20.3 Million
397,325 Added 2.73%
14,967,317 $686 Million
Q3 2022

Nov 14, 2022

BUY
$38.54 - $54.52 $44.6 Million - $63.1 Million
1,156,696 Added 8.62%
14,569,992 $706 Million
Q2 2022

Aug 12, 2022

BUY
$33.93 - $48.92 $11.8 Million - $17.1 Million
348,678 Added 2.67%
13,413,296 $527 Million
Q1 2022

May 12, 2022

BUY
$29.74 - $46.0 $3.38 Million - $5.23 Million
113,654 Added 0.88%
13,064,618 $481 Million
Q4 2021

Feb 10, 2022

SELL
$34.35 - $46.38 $10.7 Million - $14.5 Million
-311,983 Reduced 2.35%
12,950,964 $590 Million
Q3 2021

Nov 09, 2021

BUY
$18.54 - $35.74 $29.8 Million - $57.5 Million
1,608,545 Added 13.8%
13,262,947 $474 Million
Q2 2021

Aug 11, 2021

BUY
$19.79 - $26.99 $231 Million - $315 Million
11,654,402 New
11,654,402 $231 Million

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.57B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.